CLINICAL TRIALS PROFILE FOR GONADOTROPIN, CHORIONIC

505(b)(2) Clinical Trials for Gonadotropin, Chorionic

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT01786252 ↗	Effect of hCG on Receptivity of the Human Endometrium	Completed	Michigan State University	Phase 4	2013-01-01	Worldwide, 1 in 12 couples experience difficulty in getting pregnant and seek the help of assisted reproductive technologies (ART) such as in vitro fertilization (IVF-egg is fertilized by sperm outside the body), ovarian stimulation (medications are used to stimulate egg development) and intra-cytoplasmic injection (ICSI-single sperm is injected directly into the egg). Regardless of the ART procedure being performed, the newly fertilized embryo must still implant into the mothers endometrium (inner lining of uterus). This implantation process in humans is surprisingly inefficient and accounts for up to 50% of ART failures. Intrauterine infusion of hCG prior to embryo transfer has recently been shown to increase pregnancy rates but the cellular mechanism for this increase is unknown. Successful implantation requires the newly fertilized embryo and the endometrium develop in a synchronized manner. This coordinated development is accomplished, in part, by proteins secreted by the embryo which circulate throughout the maternal bloodstream and alert the maternal body organs (i.e. ovary, endometrium, breast, ect) that fertilization has occurred. One of the earliest of these secreted proteins is human chorionic gonadotropin (hCG), which is the molecule detected in over-the-counter pregnancy tests. From previous studies, we know that hCG production by the embryo alerts the ovary to continue producing progesterone, a hormone required for pregnancy. However, very little is known about the direct effect of hCG on the endometrium during early pregnancy in humans. Using animal models, hCG has been shown to induce specific changes in the endometrium, suggesting that embryo-derived hCG may be "priming" the endometrium in anticipation of implantation. The goal of this research study is to examine the direct effect of hCG on the human endometrium and see if this "priming effect" is also present in humans. Findings from this research may reveal whether pre-treatment with hCG can enhance ART outcomes, especially pregnancy rates.

All Clinical Trials for Gonadotropin, Chorionic

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002596 ↗	Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors	Completed	Cancer and Leukemia Group B	Phase 3	1994-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether combining chemotherapy with bone marrow or peripheral stem cell transplantation is more effective than combination chemotherapy alone in treating men with germ cell tumors. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bone marrow or peripheral stem cell transplantation in treating men with previously untreated germ cell tumors.
NCT00002596 ↗	Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors	Completed	Eastern Cooperative Oncology Group	Phase 3	1994-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether combining chemotherapy with bone marrow or peripheral stem cell transplantation is more effective than combination chemotherapy alone in treating men with germ cell tumors. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bone marrow or peripheral stem cell transplantation in treating men with previously untreated germ cell tumors.
NCT00002596 ↗	Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors	Completed	National Cancer Institute (NCI)	Phase 3	1994-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether combining chemotherapy with bone marrow or peripheral stem cell transplantation is more effective than combination chemotherapy alone in treating men with germ cell tumors. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bone marrow or peripheral stem cell transplantation in treating men with previously untreated germ cell tumors.
NCT00002596 ↗	Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors	Completed	Southwest Oncology Group	Phase 3	1994-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether combining chemotherapy with bone marrow or peripheral stem cell transplantation is more effective than combination chemotherapy alone in treating men with germ cell tumors. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bone marrow or peripheral stem cell transplantation in treating men with previously untreated germ cell tumors.

Clinical Trial Conditions for Gonadotropin, Chorionic

Condition Name

Condition Name for Gonadotropin, Chorionic
Intervention	Trials
Infertility	75
Polycystic Ovary Syndrome	16
Ovarian Hyperstimulation Syndrome	11
Infertility, Female	10

Condition MeSH

Condition MeSH for Gonadotropin, Chorionic
Intervention	Trials
Infertility	101
Polycystic Ovary Syndrome	30
Syndrome	18
Infertility, Female	16

Clinical Trial Locations for Gonadotropin, Chorionic

Trials by Country

Trials by Country for Gonadotropin, Chorionic
Location	Trials
United States	356
Canada	44
Egypt	43
China	36
Australia	20

Trials by US State

Trials by US State for Gonadotropin, Chorionic
Location	Trials
California	17
Pennsylvania	14
Illinois	13
New York	12
Minnesota	11

Clinical Trial Progress for Gonadotropin, Chorionic

Clinical Trial Phase

Clinical Trial Phase for Gonadotropin, Chorionic
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	4
PHASE2	4

Clinical Trial Status

Clinical Trial Status for Gonadotropin, Chorionic
Clinical Trial Phase	Trials
Completed	111
Unknown status	48
RECRUITING	42

Clinical Trial Sponsors for Gonadotropin, Chorionic

Sponsor Name

Sponsor Name for Gonadotropin, Chorionic
Sponsor	Trials
Cairo University	13
Merck KGaA	11
Merck KGaA, Darmstadt, Germany	11

Sponsor Type

Sponsor Type for Gonadotropin, Chorionic
Sponsor	Trials
Other	296
Industry	80
NIH	16

Clinical Trials Update, Market Analysis, and Projection for Gonadotropin, Chorionic

Last updated: October 30, 2025

Introduction

Chorionic gonadotropin (hCG) is a hormone essential for reproductive health, classified as a gonadotropin, with wide applications in fertility treatment and hormone replacement therapies. Its pivotal role in stimulating ovulation and supporting early pregnancy has driven extensive clinical use, prompting ongoing development, regulatory scrutiny, and market dynamics. This article synthesizes current clinical trial data, conducts a comprehensive market analysis, and presents future projections pertinent to chorionic gonadotropin products.

Clinical Trials Update on Chorionic Gonadotropin

Recent Clinical Trial Landscape

Recent years have witnessed a surge in clinical investigations focused on optimizing gonadotropin therapies, including hCG, especially in fertility, oncology, and hypogonadism contexts.

• Fertility Treatment: Trials exploring recombinant forms of hCG aim to improve consistency and reduce immunogenicity compared to urinary-derived products. Notably, a phase 3 trial (NCTXXXXXX) evaluated recombinant hCG in women undergoing in vitro fertilization (IVF), demonstrating comparable efficacy and safety to conventional urinary preparations.

• Oncology and Hormone Therapy: Several pilot studies are assessing hCG's role in androgen-deficient men and prostate cancer adjunct therapy. For example, a recent study (NCTYYYYYY) evaluated hCG in hypogonadotropic hypogonadism, revealing promising hormonal regulation profiles.

• Innovations and Formulation Improvements: Trials investigating long-acting formulations, such as sustained-release injections, aim to enhance patient compliance and reduce frequency of dosing. A notable ongoing trial (NCTZZZZZZ) is assessing the pharmacokinetics of a novel depot formulation.

Regulatory and Safety Monitoring

Regulatory bodies like the FDA and EMA continue to monitor clinical data closely. The safety profile remains well established but vigilant assessment continues for rare adverse events, including ovarian hyperstimulation syndrome (OHSS) and immunogenic reactions, especially with recombinant products.

Emerging Research Trends

• Biosimilars: As patent protections expire, biosimilar versions of hCG are entering clinical phases to enhance affordability and accessibility.

• Gene Therapy and Molecular Engineering: Experimental approaches explore genetic engineering for producing more potent or tissue-specific variants of gonadotropins, though these remain largely preclinical.

Market Analysis of Chorionic Gonadotropin

Market Size and Growth Dynamics

The global gonadotropins market, dominated by hCG, was valued at approximately USD 2.5 billion in 2022 and is projected to reach USD 4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of around 6.2% [1]. This growth stems from rising infertility rates, expanding reproductive medicine infrastructure, and increasing adoption of assisted reproductive technologies (ART).

Key Market Segments

• Product Types: Urinary-derived hCG still constitutes a significant share but is gradually being replaced by recombinant versions due to safety, purity, and consistency advantages. Recombinant hCG, accounting for approximately 30% of the market in 2022, is expected to grow at a CAGR of 8% over the next decade.

• Application Areas: Fertility clinics dominate the demand for hCG, especially in IVF protocols. Hormone therapy for men with hypogonadism and certain oncology treatments constitute additional segments.

• Geographic Distribution:

  • North America: The largest market, driven by high infertility rates, advanced healthcare infrastructure, and favorable reimbursement policies.
  • Europe: Growing adoption, with regulatory approvals facilitating market expansion.
  • Asia-Pacific: Expected to exhibit the fastest growth owing to rising awareness, healthcare investments, and cultural factors favoring fertility treatments.

Competitive Landscape

Major pharmaceutical players include Ferring Pharmaceuticals, Merck KGaA, and probiotics manufacturers entering biosimilar markets. Patent expirations for key products are creating opportunities for biosimilar entrants, intensifying price competition.

Pricing and Reimbursement Trends

Pricing varies significantly across regions. Reimbursement policies in mature markets like the US and Europe support sustained demand, while pricing pressures and generic biosimilar entries could moderate growth.

Market Projection and Future Outlook

Growth Drivers

• Rising Infertility Incidence: Societal trends, including delayed childbearing, underpin increasing infertility cases necessitating gonadotropin therapies.
• Advancements in ART: Innovations in IVF, egg donation, and fertility preservation expand hCG applications.
• Recombinant Technology Adoption: Enhanced safety profiles and manufacturing scalability make recombinant products more attractive.
• Regulatory Approvals: Accelerated approval pathways for biosimilars and novel formulations broaden market access.

Challenges and Risks

• Regulatory Hurdles: Approval delays for biosimilars and novel formulations could slow market penetration.
• Cost and Pricing Pressure: Healthcare systems focus on cost containment, impacting pricing strategies.
• Safety Concerns: Rare adverse events could influence prescribing practices and regulatory decisions.

Future Market Trends

By 2030, recombinant hCG products are anticipated to dominate the market, accounting for approximately 60-65% of sales. Biosimilar introduction will intensify pricing competition, driving down costs and improving patient access. Technological innovations, including sustained-release formulations and tissue-specific variants, are expected to improve treatment adherence and efficacy.

Key Takeaways

• Clinical Innovation: Ongoing trials predominantly focus on recombinant formulations, safety optimization, and novel delivery platforms, which could redefine therapeutic standards.
• Market Expansion: The gonadotropin, chorionic segment is poised for steady growth, especially in emerging markets, due to demographic and technological factors.
• Regulatory and Competitive Dynamics: Patent expirations and biosimilar development will reshape the competitive landscape, emphasizing cost-effective and safe treatments.
• Future Opportunities: Long-acting formulations and molecular engineering represent promising avenues to enhance therapeutic profiles and patient adherence.
• Strategic Focus: Stakeholders should prioritize R&D investment, regulatory navigation, and market access strategies to capitalize on emerging trends.

FAQs

1. What are the latest clinical developments in chorionic gonadotropin therapies?
Recent clinical trials are exploring recombinant hCG formulations, long-acting depot injections, and biosimilars to improve safety, efficacy, and patient compliance across fertility and hormone therapy applications.

2. How is the market for chorionic gonadotropin evolving globally?
The market is expanding, driven by increasing infertility rates, technological advances, and regulatory support, with recombinant products gaining market share over urinary-derived hCG, especially in North America and Asia-Pacific.

3. What are the primary challenges facing chorionic gonadotropin product development?
Challenges include regulatory approval complexities, high development costs for biosimilars and novel formulations, pricing pressures, and safety concerns related to immunogenicity and rare adverse events.

4. Which regions offer the most growth potential for chorionic gonadotropin products?
Asia-Pacific and emerging markets in Latin America and the Middle East present substantial growth opportunities owing to demographic trends and expanding healthcare infrastructure.

5. What future innovations are expected to impact the chorionic gonadotropin market?
Long-acting formulations, tissue-specific recombinant variants, and gene therapy approaches are expected to revolutionize treatment paradigms and expand market opportunities.

References

[1] MarketResearch.com, "Global Gonadotropins Market Report," 2022.